| Literature DB >> 2839404 |
K Fujiwara1, I Ogata, Y Ohta, S Hayashi, S Mishiro, K Takatsuki, Y Sato, S Yamada, K Hirata, H Oka.
Abstract
Hepatic fibrosis was induced in rats by repeated i.p. injections of pig serum. The hepatic hydroxyproline content increased to 2.1 times the normal control level at 6 weeks and to 3.2 times at 10 weeks. When P-1894B, an inhibitor of prolyl hydroxylase, was administered, there was a dose-dependent inhibition of the increase to nearly normal control levels at 6 and 10 weeks. There was also by histology a dose-dependent reduction in the degree of hepatic fibrosis. Hepatocellular damage was minimal and its extent did not vary with the degree of fibrosis or the treatment. P-1894B dose dependently reduced the hydroxylation of peptidyl proline in the fibrotic liver. These data suggest that P-1894B inhibited hepatic fibrogenesis by direct action on collagen but not by protection against hepatocellular damage leading to collagen formation. A prolyl hydroxylase inhibitor may be a candidate for use in treatment of hepatic fibrosis.Entities:
Mesh:
Substances:
Year: 1988 PMID: 2839404 DOI: 10.1002/hep.1840080418
Source DB: PubMed Journal: Hepatology ISSN: 0270-9139 Impact factor: 17.425